Yondelis Injection, Powder, Lyophilized, For Solution
Product Images NDC 59676-610

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Yondelis (NDC 59676-610). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Products, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Yondelis 01)

Chemical structure of the active ingredient Trabectedin, shown as a complex molecular diagram illustrating its atomic and bond connections.*

FDA Label Image

Figure 1 (Yondelis 02)

A survival curve chart comparing percent alive and progression-free over time in months between YONDELIS (trabectedin) and dacarabine. The graph includes censoring marks for both treatments and a table of subjects at risk over time for each drug.*

FDA Label Image

Principal Display Panel (1 Vial Carton)

YONDELIS (trabectedin) injection, powder, lyophilized for solution, 1 mg per vial. The label indicates it is for intravenous infusion only and to be reconstituted before further dilution. It is a single-dose vial with cytotoxic handling instructions. The labeler is Janssen Products, LP, and the NDC is 59676-610.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.